HIV-1 inhibitor-49_product_DataBase

Bioactivity	HIV-1 inhibitor-49 is an orally active HIV-1 inhibitor, is a HEPT analog. HIV-1 inhibitor-49 possesses great pharmacokinetics profiles and potent non-nucleoside reverse transcriptase inhibitory activity (IC50=30 nM). HIV-1 inhibitor-49 exerts potential safety without acute toxicity in mouse model[1].
Invitro	HIV-1 inhibitor-49 (化合物 9h) (EC50=17 nM-39.21 μM) 抑制 WT HIV-1，其选择性指数远高于对其他 HIV-1 突变体 (L100I, K103N, Y181C和E138K)[1]。HIV-1 inhibitor-49 (0-50 μM) 在 CHO-hERG 细胞中对 CYP2C9 和 CYP2C19 的 IC50 分别为 27.6 μM (CYP2C9)和30.3 μM (CYP2C19)，而对其他 CYP 的抑制效力 >50 μM，对 hERG 的抑制效力 >40 μM[1]。
In Vivo	HIV-1 inhibitor-49 (化合物 9h) (1000mg /kg; 灌胃; 单剂量) 在健康小鼠模型中无明显的病理损伤和死亡诱导倾向[1]。HIV-1 inhibitor-49 (10 mg/kg; 口服; 单剂量) 在大鼠中表现出良好的口服生物利用度[1]。大鼠中的药代动力谱[1]Route
Name	HIV-1 inhibitor-49
Formula	C21H18F2N2O3S
Molar Mass	416.44
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zhou RL, et al. Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs. Eur J Med Chem. 2022 Nov 24;246:114939.

PeptideDB